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Dopamine and cyclic-AMP activated phosphoprotein Mr32kDa (DARPP-32) is a cen-
tral signalling protein in neurotransmission. Following DARPP-32 phosphorylation by 
protein kinase A (PKA), DARPP-32 becomes a potent protein phosphatase 1 (PP1) 
inhibitor. DARPP-32 can itself inhibit PKA following DARPP-32 phosphorylation by 
cyclin-dependent kinase 5 (Cdk5). Increasing evidence indicates a role for DARPP-32 
and its associated signalling pathways in cancer; however, its role in ovarian cancer 
remains unclear. Using immunohistochemistry, expression of DARPP-32, PP1 and 
Cdk5 was determined in a large cohort of primary tumours from ovarian cancer pa-
tients (n = 428, 445 and 434 respectively) to evaluate associations between clinical 
outcome and clinicopathological criteria. Low cytoplasmic and nuclear DARPP-32 
expression was associated with shorter patient overall survival and progression-free 
survival (P = .001, .001, .004 and .037 respectively). Low nuclear and cytoplasmic 
DARPP-32 expression remained significantly associated with overall survival in mul-
tivariate Cox regression (P = .045, hazard ratio (HR) = 0.734, 95% confidence interval 
(CI) = 0.542-0.993 and P = .001, HR = 0.494, 95% CI = 0.325-0.749, respectively). 
High cytoplasmic and nuclear PP1 expression was associated with shorter patient 
overall survival and high cytoplasmic PP1 expression with shorter progression-free 
survival (P = .005, .033, and .037, respectively). High Cdk5 expression was associ-
ated with shorter progression-free survival (P = .006). These data suggest a role for 
DARPP-32 and associated signalling kinases as prognostic markers with clinical utility 
in ovarian cancer.
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1  | INTRODUC TION
Dopamine and cyclic-AMP (cAMP)-regulated phosphoprotein 
Mr32kDa (DARPP-32) is a target of dopamine and cAMP and is 
found enriched in dopaminoceptive nerve terminals where it acts 
as a central signalling molecule. Dependent upon its phosphory-
lation state, DARPP-32 has been shown to act as a phosphatase 
inhibitor or a kinase. DARPP-32 acts as an inhibitor of protein 
phosphatase 1 (PP1) and protein kinase A (PKA).1 Phosphorylation 
at Threonine (Thr)-34 by PKA converts DARPP-32 to a potent in-
hibitor of PP1, whereas phosphorylation at Thr-75 by cyclin-de-
pendent kinase 5 (Cdk5) or cell division cycle (cdc)2 converts 
DARPP-32 into a PKA inhibitor.2 There is further complexity in this 
signalling, with phosphorylation of DARPP-32 Serine (Ser)-137 by 
casein kinase 1 (CK1) able to prevent dephosphorylation of Thr-
34.3 A truncated DARPP-32 splice variant, t-DARPP, exists that 
TA B L E  1   Associations between the cytoplasmic and nuclear expression of DARPP-32, PP1 and Cdk5 determined using  
immunohistochemistry with clinicopathological variables. The P values are resultant from Pearson's χ2 test of association, and  
significant values (P ≤ .05) are highlighted in bold
DARPP-32 PP1 Cdk5
Cytoplasmic expression Nuclear expression Cytoplasmic expression Nuclear expression Cytoplasmic expression Nuclear expression
Low High P Low High P Low High P Low High P Low High P Low High P
Patient age
62 years and below 159 (37.1%) 33 (7.7%) .947 119 (27.9%) 73 (17.1%) .412 164 (36.9%) 35 (7.9%) .465 97 (21.8%) 101 (22.7%) .115 118 (27.3%) 80 (18.5%) .283 68 (15.7%) 130 (30.0%) .302
Older than 62 196 (45.9%) 40 (9.4%) 154 (36.2%) 80 (18.8%) 196 (44.0%) 50 (11.2%) 139 (31.3%) 107 (24.1%) 128 (29.6%) 107 (24.7%) 92 (21.2%) 143 (33.0%)
Figo stage
1 122 (28.9%) 26 (6.2%) .926 88 (21.0%) 60 (14.3%) .258 147 (33.4%) 13 (3.0%) <.001 96 (21.9%) 63 (14.4%) .147 101 (23.8%) 52 (12.1%) .004 74 (17.3%) 79 (18.5%) .002
2 41 (9.7%) 8 (1.9%) 32 (7.6%) 16 (3.8%) 37 (8.4%) 12 (2.7%) 23 (5.2%) 26 (5.9%) 27 (6.3%) 18 (4.2%) 18 (4.2%) 27 (6.3%)
3 160 (37.9%) 34 (8.1%) 126 (30.0%) 67 (16.0%) 148 (33.6%) 53 (12.0%) 104 (23.7%) 97 (22.1%) 96 (22.4%) 106 (24.8%) 57 (13.3%) 145 (33.9%)
4 27 (6.4%) 4 (0.9%) 24 (5.7%) 7 (1.7%) 23 (5.2%) 7 (1.6%) 13 (3.0%) 17 (3.9%) 18 (4.2) 10 (2.3%) 10 (2.3%) 18 (4.2%)
Tumour grade
1 25 (6.1%) 10 (2.3%) .041 16 (3.8%) 19 (4.5%) <.001 33 (7.4%) 2 (0.4%) .002 24 (5.4%) 11 (2.5%) .115 26 (6.0%) 11 (2.5%) .151 19 (4.4%) 18 (4.1%) .045
2 24 (11.2%) 15 (3.5%) 27 (6.3%) 36 (8.5%) 59 (13.3%) 5 (1.1%) 32 (7.2%) 32 (7.2%) 38 (8.8%) 25 (5.8%) 28 (6.5%) 35 (8.1%)
3 281 (65.7%) 48 (11.2%) 230 (54.0%) 98 (23.0%) 268 (60.2%) 78 (17.5%) 180 (40.5%) 165 (37.2%) 182 (41.9%) 152 (35.0%) 113 (26.0%) 221 (50.9%)
Residual disease
No residual tumour 183 (48.4%) 42 (11.1%) .232 135 (35.9%) 90 (23.9%) .137 217 (54.7%) 28 (7.1%) <.001 147 (37.1%) 97 (24.5%) .010 149 (38.9%) 87 (22.7%) .001 101 (26.4%) 135 (35.2%) .017
Residual 
tumour < 2 cm
35 (9.3%) 11 (2.9%) 14 (9.0%) 11 (9.2%) 35 (8.8%) 13 (3.3%) 19 (4.8%) 29 (7.3%) 20 (5.2%) 27 (7.0%) 12 (3.1%) 35 (9.1%)
Residual 
tumour > 2 cm
93 (24.6%) 14 (3.7%) 68 (18.1%) 38 (10.1%) 72 (18.1%) 32 (8.1%) 50 (12.6%) 54 (13.6%) 44 (11.5%) 56 (14.6%) 30 (7.8%) 70 (18.3%)
Response to chemotherapy
Refractory 24 (8.8%) 5 (1.8%) .360 23 (8.5%) 6 (2.2%) .210 29 (10.1%) 5 (1.7%) .123 22 (7.7%) 12 (4.2%) .43 16 (5.7%) 16 (5.7%) .704 10 (3.5%) 22 (7.8%) .787
Relapsed within 
6 months
18 (6.6%) 1 (0.4%) 13 (4.8%) 6 (2.2%) 20 (6.9%) 1 (0.3%) 12 (4.2%) 9 (3.1%) 9 (3.2%) 11 (3.9%) 7 (2.5%) 13 (4.6%)
Relapsed after 
6 months




225 (52.6%) 41 (9.6%) .028 180 (42.3%) 85 (20.0%) <.001 196 (44.0%) 78 (17.5%) <.001 132 (29.7%) 141 (31.8%) .182 127 (29.3%) 139 (32.0%) <.001 74 (17.1%) 192 (44.2%) <.001
Mucinous 33 (7.7%) 9 (2.1%) 20 (4.7%) 22 (5.2%) 40 (9.0%) 1 (0.2%) 23 (5.2%) 18 (4.1%) 29 (6.7%) 15 (3.5%) 22 (5.1%) 22 (5.1%)
Endometrioid 36 (8.4%) 16 (3.7%) 22 (5.2%) 30 (7.0%) 48 (10.8%) 3 (0.7%) 33 (7.4%) 18 (4.1%) 34 (7.8%) 20 (4.6%) 28 (65%) 26 (6.0%)
Clear cell carcinoma 37 (8.6%) 1 (0.2%) 37 (8.7%) 1 (0.2%) 48 (10.8%) 0 (0.0%) 29 (6.5%) 19 (22.5%) 38 (8.8%) 3 (0.7%) 24 (5.5%) 17 (3.9%)
Low-grade serous 
carcinoma
17 (4.0%) 4 (0.9%) 11 (2.6%) 9 (2.1%) 18 (4.0%) 2 (0.4%) 13 (2.9%) 7 (1.6%) 10 (2.3%) 8 (1.8%) 8 (1.8%) 10 (2.3%)
Borderline serous 
carcinoma
6 (1.4%) 2 (0.5%) 2 (0.5%) 6 (1.4%) 10 (2.2%) 1 (0.2%) 6 (1.4%) 5 (1.1%) 8 (1.8%) 3 (0.7%) 4 (0.9%) 7 (1.6%)
Borderline mucinous 
carcinoma
1 (0.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
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has an alternate translational start in exon 2. The t-DARPP splice 
variant lacks the Thr-34 phosphorylation site and consequently, it 
is unable to inhibit PP1. DARPP-32 and t-DARPP expression, in-
cluding DARPP-32 to t-DARPP expression ratios, have been linked 
with patient survival in a number of tumour types, including breast, 
non-small cell lung, gastric colorectal and oesophageal cancers.4-9 
Expression of t-DARPP has been shown in gastric, non-small cell 
lung and breast cancer, amongst other tumour types.4,6,10
DARPP-32 acts as a central signalling protein in neurotransmis-
sion through its inhibition of PP1 and PKA. PP1 is a heterotrimer 
and acts as a Ser/Thr phosphatase in many important cellular func-
tions, including mitosis.11 In cancer, amplification of the PPP1CA 
gene causes aberrant activation of mitogen-activated protein kinase 
(MAPK) in prostate cancer,12 and in glioblastoma, nuclear PP1A ex-
pression is associated with survival of patients with p53 expressing 
tumours.13
TA B L E  1   Associations between the cytoplasmic and nuclear expression of DARPP-32, PP1 and Cdk5 determined using  
immunohistochemistry with clinicopathological variables. The P values are resultant from Pearson's χ2 test of association, and  
significant values (P ≤ .05) are highlighted in bold
DARPP-32 PP1 Cdk5
Cytoplasmic expression Nuclear expression Cytoplasmic expression Nuclear expression Cytoplasmic expression Nuclear expression
Low High P Low High P Low High P Low High P Low High P Low High P
Patient age
62 years and below 159 (37.1%) 33 (7.7%) .947 119 (27.9%) 73 (17.1%) .412 164 (36.9%) 35 (7.9%) .465 97 (21.8%) 101 (22.7%) .115 118 (27.3%) 80 (18.5%) .283 68 (15.7%) 130 (30.0%) .302
Older than 62 196 (45.9%) 40 (9.4%) 154 (36.2%) 80 (18.8%) 196 (44.0%) 50 (11.2%) 139 (31.3%) 107 (24.1%) 128 (29.6%) 107 (24.7%) 92 (21.2%) 143 (33.0%)
Figo stage
1 122 (28.9%) 26 (6.2%) .926 88 (21.0%) 60 (14.3%) .258 147 (33.4%) 13 (3.0%) <.001 96 (21.9%) 63 (14.4%) .147 101 (23.8%) 52 (12.1%) .004 74 (17.3%) 79 (18.5%) .002
2 41 (9.7%) 8 (1.9%) 32 (7.6%) 16 (3.8%) 37 (8.4%) 12 (2.7%) 23 (5.2%) 26 (5.9%) 27 (6.3%) 18 (4.2%) 18 (4.2%) 27 (6.3%)
3 160 (37.9%) 34 (8.1%) 126 (30.0%) 67 (16.0%) 148 (33.6%) 53 (12.0%) 104 (23.7%) 97 (22.1%) 96 (22.4%) 106 (24.8%) 57 (13.3%) 145 (33.9%)
4 27 (6.4%) 4 (0.9%) 24 (5.7%) 7 (1.7%) 23 (5.2%) 7 (1.6%) 13 (3.0%) 17 (3.9%) 18 (4.2) 10 (2.3%) 10 (2.3%) 18 (4.2%)
Tumour grade
1 25 (6.1%) 10 (2.3%) .041 16 (3.8%) 19 (4.5%) <.001 33 (7.4%) 2 (0.4%) .002 24 (5.4%) 11 (2.5%) .115 26 (6.0%) 11 (2.5%) .151 19 (4.4%) 18 (4.1%) .045
2 24 (11.2%) 15 (3.5%) 27 (6.3%) 36 (8.5%) 59 (13.3%) 5 (1.1%) 32 (7.2%) 32 (7.2%) 38 (8.8%) 25 (5.8%) 28 (6.5%) 35 (8.1%)
3 281 (65.7%) 48 (11.2%) 230 (54.0%) 98 (23.0%) 268 (60.2%) 78 (17.5%) 180 (40.5%) 165 (37.2%) 182 (41.9%) 152 (35.0%) 113 (26.0%) 221 (50.9%)
Residual disease
No residual tumour 183 (48.4%) 42 (11.1%) .232 135 (35.9%) 90 (23.9%) .137 217 (54.7%) 28 (7.1%) <.001 147 (37.1%) 97 (24.5%) .010 149 (38.9%) 87 (22.7%) .001 101 (26.4%) 135 (35.2%) .017
Residual 
tumour < 2 cm
35 (9.3%) 11 (2.9%) 14 (9.0%) 11 (9.2%) 35 (8.8%) 13 (3.3%) 19 (4.8%) 29 (7.3%) 20 (5.2%) 27 (7.0%) 12 (3.1%) 35 (9.1%)
Residual 
tumour > 2 cm
93 (24.6%) 14 (3.7%) 68 (18.1%) 38 (10.1%) 72 (18.1%) 32 (8.1%) 50 (12.6%) 54 (13.6%) 44 (11.5%) 56 (14.6%) 30 (7.8%) 70 (18.3%)
Response to chemotherapy
Refractory 24 (8.8%) 5 (1.8%) .360 23 (8.5%) 6 (2.2%) .210 29 (10.1%) 5 (1.7%) .123 22 (7.7%) 12 (4.2%) .43 16 (5.7%) 16 (5.7%) .704 10 (3.5%) 22 (7.8%) .787
Relapsed within 
6 months
18 (6.6%) 1 (0.4%) 13 (4.8%) 6 (2.2%) 20 (6.9%) 1 (0.3%) 12 (4.2%) 9 (3.1%) 9 (3.2%) 11 (3.9%) 7 (2.5%) 13 (4.6%)
Relapsed after 
6 months




225 (52.6%) 41 (9.6%) .028 180 (42.3%) 85 (20.0%) <.001 196 (44.0%) 78 (17.5%) <.001 132 (29.7%) 141 (31.8%) .182 127 (29.3%) 139 (32.0%) <.001 74 (17.1%) 192 (44.2%) <.001
Mucinous 33 (7.7%) 9 (2.1%) 20 (4.7%) 22 (5.2%) 40 (9.0%) 1 (0.2%) 23 (5.2%) 18 (4.1%) 29 (6.7%) 15 (3.5%) 22 (5.1%) 22 (5.1%)
Endometrioid 36 (8.4%) 16 (3.7%) 22 (5.2%) 30 (7.0%) 48 (10.8%) 3 (0.7%) 33 (7.4%) 18 (4.1%) 34 (7.8%) 20 (4.6%) 28 (65%) 26 (6.0%)
Clear cell carcinoma 37 (8.6%) 1 (0.2%) 37 (8.7%) 1 (0.2%) 48 (10.8%) 0 (0.0%) 29 (6.5%) 19 (22.5%) 38 (8.8%) 3 (0.7%) 24 (5.5%) 17 (3.9%)
Low-grade serous 
carcinoma
17 (4.0%) 4 (0.9%) 11 (2.6%) 9 (2.1%) 18 (4.0%) 2 (0.4%) 13 (2.9%) 7 (1.6%) 10 (2.3%) 8 (1.8%) 8 (1.8%) 10 (2.3%)
Borderline serous 
carcinoma
6 (1.4%) 2 (0.5%) 2 (0.5%) 6 (1.4%) 10 (2.2%) 1 (0.2%) 6 (1.4%) 5 (1.1%) 8 (1.8%) 3 (0.7%) 4 (0.9%) 7 (1.6%)
Borderline mucinous 
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DARPP-32 phosphorylation of Thr-75 by Cdk5 allows DARPP-32 
to function as a PKA inhibitor. Cdk5 is considered a neuronal serine/
threonine kinase that is predominantly activated by p35 or p39; its 
function has been implicated in a number of tumourigenic pathways, 
with a number of important substrates in addition to DARPP-32, in-
cluding p53 and AKT (reviewed in Ref. [14]). Studies in a number of 
tumour types have demonstrated that high Cdk5 expression is asso-
ciated with clinicopathological criteria associated with poor progno-
sis, and in some cases, shortened disease-specific survival itself15-17; 
however, the reverse has been observed in gastric cancer.18,19
There is increasing evidence that DARPP-32, PP1 and Cdk5 have 
a role in various tumour types; however, expression of DARPP-32 
and PP1 has not previously been described in ovarian cancer, al-
though DARPP-32 has been implicated in follicular development.20 
In ovarian cancer, in vitro studies have indicated a role for Cdk5 in 
paclitaxel sensitivity,21 DNA damage response,22 mitosis23 and AKT 
activation.24 Ovarian cancer is the seventh most common cancer in 
woman globally, and five-year survival is around 45%.25 Treatment 
for ovarian cancer principally consists of surgery and platinum-based 
chemotherapy. The current study sought to determine DARPP-32, 
PP1 and Cdk5 expression in ovarian cancer and determine their rela-
tionships with patient survival.
2  | MATERIAL S AND METHODS
2.1 | Patient cohorts
Patients received treatment at Nottingham University Hospitals be-
tween 1991 and 2011. Progression-free survival was defined as the 
length between the start of treatment and clinical identification of 
recurrence or last follow-up date. Overall survival was defined as 
the length between the start of treatment and date of death or last 
follow-up date. Median follow-up was 100 months determined using 
the reverse Kaplan-Meier method, and clinicopathological charac-
teristics of the cohort are shown in Table 1. Clinicopathological in-
formation available included patient age, Figo stage, tumour grade, 
residual disease, response to chemotherapy and histological sub-
type. Age was categorized based on the median age of the patient 
cohort. Suboptimal debulking was classified as residual disease of 
>2 cm. Data on chemotherapy resistance were recorded accord-
ing to the Gynaecological Oncology Group (COG) as refractory 
(not responding to chemotherapy), resistant (an initial response to 
chemotherapy with recurrence within 6 months) or sensitive (either 
no recurrence, or recurrence after 6 months). Ethical approval was 
obtained from Derbyshire Ethics Committee (07/H0401/156), This 
study is reported in accordance to REMARK criteria.26
2.2 | Immunohistochemistry
Immunohistochemical staining was conducted using a Novolink 
Polymer Detection kit (Leica) on a tissue microarray comprised of 
single 0.6mm cores from 575 ovarian tumours taken from a rep-
resentative area as assessed by a specialist ovarian cancer histo-
pathologist; the use of which has been described previously.27-29 
Staining was conducted according to manufacturers’ instructions 
and has been described previously.30 Briefly, tissue was depar-
affinized in xylene, rehydrated in ethanol then water and heated 
in a microwave for 10 minutes at 750 W followed by 10 minutes 
at 450 W in 0.01 mol L−1 sodium citrate buffer (pH6.0). Novolink 
Peroxidase Block was incubated on the tissue, washed with Tris-
buffered saline (TBS), followed by incubation with Novolink 
Protein Block solution. Rabbit polyclonal anti-DARPP-32 (Abcam 
ab40801) diluted 1:500, anti-Cdk5 (Cell Signalling Technology 
1H3) diluted 1:500 and anti-PP1 (Life Technologies 10C6-3) diluted 
1:50 were used as the primary antibodies; each was incubated on 
tissue for one hour at room temperature; with antibody specificity 
confirmed prior to use in immunohistochemistry by Western blot-
ting. Tissue was washed with TBS prior to incubation with Novolink 
Post Primary solution, which was subsequently washed with TBS 
and then incubation with Novolink Polymer solution. 3,3’ diamin-
obenzidine was used as the chromogenic substrate to develop im-
munohistochemical reactions and tissue was counterstained with 
haematoxylin. Positive and negative controls were included with 
each staining run and were comprised of breast tumour composite 
sections comprising grade 1 and 2 early stage invasive tumours; 
negative controls had primary antibody omitted from each stain-
ing run.
Slides were scanned using a Nanozoomer Digital Pathology 
Scanner (Hamamatsu Photonics), and staining was assessed at 
200× magnification. Staining in the cytoplasm was assessed using 
a semi-quantitative immunohistochemical H score, where staining 
intensity within tumour cells was assessed as none (0), weak (1), me-
dium (2) or strong (3) over the percentage area of each staining in-
tensity. Staining in the nucleus was examined in a semi-quantitative 
manner, where the percentage of tumour cells that demonstrated 
any staining intensity was assessed. Greater than 30% of cores for 
each TMA were double assessed, with both assessors blinded to 
clinical outcome and each other's scores.
2.3 | Statistical analyses
Statistical analysis was performed using IBM SPSS Statistics (ver-
sion 26). Cases were stratified based on overall survival using 
X-Tile software.31 All differences were deemed statistically sig-
nificant at the level of P ≤ .05. The Pearson χ2 test of association 
was used to determine the relationship between categorized pro-
tein expression and clinicopathological variables. Survival curves 
were plotted according to the Kaplan-Meier method with signifi-
cance determined using the log-rank test. Cox proportional haz-
ards regression model was used for multivariate survival analysis. 
The primary end point of this study was to determine whether 
the expression of protein was associated with overall survival of 
ovarian cancer patients.
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3  | RESULTS
3.1 | DARPP-32, PP1 and Cdk5 protein staining 
location and frequency
Protein expression was assessed in ovarian cancer tissue; 428, 
445 and 434 patients were available for assessment for DARPP-
32, PP1 and Cdk5, respectively. Different numbers of patient 
specimens were available due to core attrition and/or insufficient 
tumour available to score. Nuclear and cytoplasmic expression 
of DARPP-32, PP1 and Cdk5 was observed and staining varied 
from weak to intense, with heterogeneity observed between ad-
jacent tumour cells. Representative photomicrographs are shown 
in Figure 1.
Nuclear DARPP-32 expression had a median H-score of 10 
and ranged from 0 to 100 with cytoplasmic DARPP-32 expression 
having a median H-score of 65 and ranging from 0 to 300. X-tile 
was used to generate cut points based on overall survival; nuclear 
DARPP-32 expression had a cut point of 30 and 64.1% of cases 
(227/426) demonstrated low expression. Cytoplasmic DARPP-32 
F I G U R E  1   Representative 
immunohistochemical staining of 
DARPP-32, PP1 and Cdk5. Low 
expression of DARPP-32 (A), high 
expression of DARPP-32 (B); low 
expression of PP1 (C), high expression of 
PP1 (D). Low expression of Cdk5 (E) and 
high expression of Cdk5 (F) are shown. 
100× magnification is shown, with a 200× 
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expression had a cut point of 175 and 82.9% of cases (355/428) had 
low expression. Nuclear PP1 expression had a median H-score of 
60 and ranged from 0 to 100 and cytoplasmic PP1 expression had 
a median H-score of 90 and ranged from 0 to 280. Nuclear PP1 had 
a cut point of 60 and 53.2% of cases (236/444) demonstrated low 
expression; cytoplasmic PP1 had a cut point of 140 and 80.9% of 
cases (360/445) demonstrated low expression. Nuclear Cdk5 ex-
pression had a median H-score of 10 and ranged from 0-100 and 
cytoplasmic Cdk5 expression had a median H-score of 120 and 
ranged from 0-270. Nuclear Cdk5 had a cut point of 10 and 36.9% 
of cases (160/434) demonstrated low expression; cytoplasmic 
Cdk5 had a cut point of 130 and 56.7% of cases (246/434) demon-
strated low expression.
3.2 | Relationship between DARPP-32, 
PP1 and Cdk5
The relationship between DARPP-32, PP1 and Cdk5 cytoplasmic 
and nuclear expression was explored using the Spearman rank cor-
relation coefficient. DARPP-32 cytoplasmic expression was sig-
nificantly correlated with DARPP-32 nuclear expression (r2 = .858, 
P < .001). PP1 cytoplasmic expression was significantly correlated 
with PP1 nuclear expression (r2 = .487, P < .001). Cdk5 cytoplasmic 
expression was significantly correlated with Cdk5 nuclear expres-
sion (r2 = .615, P < .001). All of these correlations indicate a strong 
biological relationship between nuclear and cytoplasmic expression 
of each protein that has not been assessed further within this study.
F I G U R E  2   Kaplan-Meier analysis of ovarian cancer overall survival showing the impact of low (black line) and high (grey line) DARPP-32 
expression within the cytoplasm (A) and nucleus (B), PP1 expression within the cytoplasm (C) and nucleus (D) and Cdk5 expression within 
the cytoplasm (E) and nucleus (F). Significance was determined using the log-rank test
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DARPP-32 cytoplasmic expression was correlated with PP1 
cytoplasmic (r2 = .285, P < .001), PP1 nuclear (r2 = .147, P < .001), 
Cdk5 cytoplasmic (r2 = .271, P < .001) and Cdk5 nuclear expres-
sion (r2 = .200, P < .001). DARPP-32 nuclear expression was 
correlated with PP1 cytoplasmic (r2 = .146, P < .001) and Cdk5 
cytoplasmic expression (r2 = .188, P < .001), but not PP1 nu-
clear (r2 = .081, P = .110) and Cdk5 nuclear expression (r2 = .100, 
P = .51). Cytoplasmic PP1 expression was correlated with Cdk5 
cytoplasmic (r2 = .610, P < .001) and nuclear expression (r2 = .357, 
P < .001). Nuclear PP1 expression was correlated with Cdk5 
cytoplasmic (r2 = .304, P < .001) and Cdk5 nuclear expression 
(r2 = .440, P < .001).
3.3 | Relationship between DARPP-32, 
PP1 and Cdk5 protein expression and 
clinicopathological variables
Pearson's chi-squared tests were performed to evaluate the relation-
ships between DARPP-32, PP1 and Cdk5 expression with available 
clinicopathological criteria (Table 1). Low nuclear DARPP-32 expres-
sion was associated with grade 3 tumours (χ2 = 22.660, df = 2, P < .001) 
and tumour histology (χ2 = 42.236, df = 6, P < .001; Table 1). Low cy-
toplasmic DARPP-32 expression was associated with grade 2 tumours 
(χ2 = 6.371, df = 2, P = .041) and tumour histology (χ2 = 14.197, df = 6, 
P = .028; Table 1). Low nuclear expression of PP1 was associated with 
F I G U R E  3   Kaplan-Meier analysis of ovarian progression-free survival showing the impact of low (black line) and high (grey line) 
DARPP-32 expression within the cytoplasm (A) and nucleus (B), PP1 expression within the cytoplasm (C) and nucleus (D) and Cdk5 
expression within the cytoplasm (E) and nucleus (F). Significance was determined using the log-rank test
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absence of residual disease (χ2 = 9.287, df = 2, P = .010; Table 1). Low 
cytoplasmic expression of PP1 was associated with lower Figo stage 
(χ2 = 20.422, df = 3, P < .001), lower tumour grade (χ2 = 11.990, df = 2, 
P = .002), absence of residual disease (χ2 = 20.949, df = 2, P < .001) and 
tumour histology (χ2 = 41.807, df = 5, P < .001; Table 1). Low nuclear 
Cdk5 expression was associated with lower Figo stage (χ2 = 15.327, 
df = 3, P = .002), lower tumour grade (χ2 = 6.211, df = 2, P = .045), ab-
sence of residual disease (χ2 = 8.107, df = 2, P = .017) and tumour his-
tology (χ2 = 26.522, df = 6, P < .001; Table 1). Low cytoplasmic Cdk5 
expression was associated with lower Figo stage (χ2 = 13.172, df = 3, 
P = .004) tumour histology (χ2 = 33.852, df = 6, P < .001) and the ab-
sence of residual disease (χ2 = 14.121, df = 2, P = .001; Table 1).
3.4 | Association between DARPP-32, PP1 and 
Cdk5 protein expression and overall survival
Low DARPP-32 expression in the cytoplasm and in the nucleus was 
associated with adverse survival (both P = .001; Figure 2A,B). Low 
nuclear DARPP-32 expression remained significantly associated 
with survival in multivariate Cox regression (P = .045, hazard ratio 
(HR) = 0.734, 95% confidence interval (CI) = 0.542-0.993), when Figo 
stage, residual disease, tumour grade, tumour histology and median 
patient age were included (all with individual Kaplan-Meier statis-
tics of P = .001 or below). Low cytoplasmic DARPP-32 expression 
also remained significant in multivariate Cox regression (P = .001, 
HR = 0.494, 95% CI = 0.325-0.749) when the same variables were 
included. Low cytoplasmic and nuclear PP1 expression was associ-
ated with improved survival (P = .005 and .033) (Figure 2C,D); low 
cytoplasmic and nuclear PP1 expression was not associated with 
survival in multivariate Cox regression (P = .434, HR = 0.874, 95% 
CI = 0.624-1.225 and P = .245, HR = 1.178, 95% CI = 0.894-1.552). 
Cdk5 cytoplasmic and nuclear expression was not associated with 
patient survival (Figure 2E,F).
3.5 | Association between DARPP-32, PP1 and 
Cdk5 protein expression and progression-free survival
Low DARPP-32 expression in the cytoplasm and in the nucleus was 
also associated with shorter progression-free survival (P = .004 
and .037, respectively) (Figure 3A,B). Low cytoplasmic DARPP-32 
F I G U R E  4   Kaplan-Meier analysis 
of ovarian overall survival showing the 
impact of the combination of cytoplasmic 
DARPP-32 expression with cytoplasmic 
PP1 expression (A) and cytoplasmic Cdk5 
expression (B). Low DARPP-32 expression 
is indicated by a black line and high 
DARPP-32 expression is indicated by a 
grey line. The dashed line indicates low 
PP1 or Cdk5 expression, and the solid line 
indicates high PP1 or Cdk5 expression. 
Significance was determined using the 
log-rank test
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expression remained significantly associated with progression-
free survival in multivariate Cox regression (P = .006, HR = 0.546, 
95% CI = 0.355-0.840), when Figo stage, residual disease, tumour 
grade, tumour histology and median patient age were included (all 
with individual Kaplan-Meier statistics of P = .001 or below). Low 
PP1 expression in the cytoplasm, but not the nucleus was associ-
ated with improved progression-free survival (P = .037; Figure 3C,D); 
PP1 cytoplasmic expression was not associated with progression-
free survival in multivariate Cox regression (P = .143, HR = 0.772, 
95% CI = 0.545-1.092). Low cytoplasmic Cdk5 expression, but not 
nuclear expression, was associated with improved progression-free 
survival (P = .006; Figure 3E,F); Cdk5 cytoplasmic expression was 
not associated with progression-free survival in multivariate Cox re-
gression (P = .962, HR = 1.007, 95% CI = 0.750-1.352).
3.6 | Association between DARPP-32, PP1 and 
Cdk5 protein expression and overall survival in high-
grade serous carcinomas
Expression levels of DARPP-32, PP1 and Cdk5 were assessed in the 
high-grade serous carcinoma histological subtype. In this histological 
group, DARPP-32 cytoplasmic and nuclear expression, PP1 cytoplasmic 
and nuclear expression and Cdk5 cytoplasmic and nuclear expression 
were not associated with overall survival (P = .073, .098, .518, .294, .815 
and .497, respectively). Other histological subtypes were not individu-
ally assessed as they had limited events available for assessment.
3.7 | Association between DARPP-32, 
PP1 and Cdk5 protein expression combinations and 
overall survival
High and low cytoplasmic DARPP-32 expression in high and low 
expression groups of cytoplasmic PP1 and Cdk5 were assessed to 
understand the impact of these proteins on patient survival. The 
combination of low DARPP-32 expression and high PP1 expression 
was associated with shorter overall survival (P < .001; Figure 4A). 
Low DARPP-32 and high Cdk5 expression was associated with 
shorter overall survival (P < .001; Figure 4B).
4  | DISCUSSION
Increasing evidence suggests a role for DARPP-32 in cancer; how-
ever, its role in ovarian cancer remains unclear. This study inves-
tigated the expression of DARPP-32, PP1 and Cdk5 in a cohort of 
ovarian cancer patients. Low cytoplasmic and nuclear DARPP-32 
expression was associated with shorter overall survival (P = .001 
and .001, respectively) in the total patient cohort. Importantly, cy-
toplasmic and nuclear DARPP-32 expression remained significantly 
associated with overall survival when other potential confounding 
factors were included in multivariate analysis (P = .001 and .045 
respectively). In addition to survival, both nuclear and cytoplasmic 
DARPP-32 expression were linked with tumour grade and tumour 
histology. Limited studies have assessed expression of DARPP-32 
in cancer, with no previous descriptions in ovarian cancer. In breast 
cancer, low expression of DARPP-32 was associated with adverse 
patient survival9; in colorectal cancer and glioblastoma multiforme, 
high expression of DARPP-32 was associated with adverse sur-
vival.8,32 In non-small cell lung and breast cancer, a high t-DARPP 
to DARPP-32 ratio was associated with shorter survival.4,7 Studies 
in murine mammary tumourigenesis suggest that DARPP-32 is ex-
pressed in normal tissue and in some breast tumours, with t-DARPP 
expressed only in tumours; this indicates a shift from DARPP-32 to t-
DARPP expression during tumourigenesis.10 Whilst the importance 
of DARPP-32, t-DARPP and the ratio thereof in tumourigenesis re-
mains to be fully understood, evidence in breast cancer implies that 
DARPP-32 plays a role in inhibiting cell growth, whilst t-DARPP ac-
celerates it. In this study, the epitope for the DARPP-32 antibody 
used for immunohistochemistry was located within amino acids 
0-30, meaning that DARPP-32 and not t-DARPP was assessed.
Expression of PP1 and Cdk5 was assessed in ovarian cancer, 
with high cytoplasmic and nuclear PP1 expression associated with 
adverse survival (P = .005 and .033, respectively). No association 
between Cdk5 expression and overall patient survival was observed. 
Cdk5 expression has been assessed in a number of other tumour 
types; with low Cdk5 expression associated with adverse survival 
in gastric cancer18 and in breast cancer.33 In addition to survival, cy-
toplasmic PP1 expression was associated with Figo stage, tumour 
grade, residual disease and histological subtype; with nuclear PP1 
expression associated with residual disease and histological subtype. 
Cytoplasmic Cdk5 expression was associated with Figo stage, resid-
ual disease and histological subtype, with nuclear Cdk5 expression 
associated with tumour grade in addition. These clinicopathological 
criteria are indicators of poor prognosis and are in line with the asso-
ciations observed with patient outcome.
In addition to overall survival, we were also able to test associa-
tions with progression-free survival of ovarian cancer patients. Low 
cytoplasmic and nuclear DARPP-32 expression, high cytoplasmic 
PP1 expression and high cytoplasmic Cdk5 expression were associ-
ated with shorter progression-free survival. As none of the proteins 
were associated with response to chemotherapy this suggests that 
the association with progression-free survival is not linked with al-
tered sensitivity to chemotherapy.
Finally, low expression of DARPP-32 in tumours with high expres-
sion of Cdk5 or PP1 was more strongly associated with shorter survival 
that the alternative combinations. These combined results suggest a 
loss of DARPP-32 and/or protein function may be important in ovarian 
cancer, in particular those with high expression levels of PP1 or Cdk5.
5  | CONCLUSION
Low cytoplasmic and nuclear DARPP-32 expression and high cy-
toplasmic and nuclear PP1 expression are associated with shorter 
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survival in ovarian cancer patients. Importantly, both cytoplas-
mic and nuclear expression of DARPP-32 remain associated with 
overall survival when other confounding factors are included in 
multivariate analysis. In addition, low cytoplasmic and nuclear 
DARPP-32, high cytoplasmic PP1 and high cytoplasmic Cdk5 
expression is associated with adverse progression-free survival. 
These findings warrant further investigation in larger patient co-
horts but indicate that DARPP-32 expression may be of clinical 
relevance in ovarian cancer.
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